Cargando…
Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration
BACKGROUND: The potential benefits of conbercept, aflibercept, and ranibizumab has been reported in patients with wet age-related macular degeneration (wAMD). However, their economic outcomes are still unclear. The current study would assess the cost-effectiveness of conbercept, aflibercept and rani...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475432/ https://www.ncbi.nlm.nih.gov/pubmed/32953739 http://dx.doi.org/10.21037/atm-20-1334 |